<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DORZOLAMIDE HYDROCHLORIDE</span><br/>(dor-zol'a-mide)<br/><span class="topboxtradename">Trusopt<br/></span><b>Classifications:</b> <span class="classification">eye preparation</span>; <span class="classification">carbonic anhydrase inhibitor</span><br/><b>Prototype: </b>Acetazolamide<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2% ophthalmic solution</p>
<h1><a name="action">Actions</a></h1>
<p>Dorzolamide is a sulfonamide and inhibits carbonic anhydrase in the eye, thus reducing the rate of aqueous humor formation
         with subsequent lowering of IOP. Elevated IOP is a major risk factor in the pathogenesis of optic nerve damage and visual
         field loss due to glaucoma.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers IOP in glaucoma or ocular hypertension.</p>
<h1><a name="uses">Uses</a></h1>
<p>Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Previous hypersensitivity to dorzolamide; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of hypersensitivity to other carbonic anhydrase inhibitors, sulfonamides, or thiazide diuretics; ocular infection
         or inflammation; recent ocular surgery; moderate-to-severe renal or hepatic insufficiency; angle-closure glaucoma; concomitant
         use of oral carbonic anhydrase inhibitors; older adults, corneal abrasion.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Glaucoma, Ocular Hypertension</span><br/><span class="rdage">Adult/Child:</span> <span class="rdroute">Ophthalmic</span> 1 drop in affected eye t.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Instillation</span><br/><ul>
<li>Apply gentle pressure to lacrimal sac during and immediately following drug instillation for about 1 min to lessen degree
            of systemic absorption.
         </li>
<li>Administer at least 10 min apart, if another ophthalmic drug is being used concurrently.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache. <span class="typehead">GI:</span> Bitter taste, nausea. <span class="typehead">Special Senses:</span> <span class="speceff-common">Transient burning or stinging, transient blurred vision,</span> superficial punctate keratitis, tearing, dryness, photophobia, ocular allergic reaction. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Some systemic absorption from topical instillation. <span class="typehead">Onset:</span> 2 h. <span class="typehead">Duration:</span> 812 h. <span class="typehead">Distribution:</span> Distributes into red blood cells. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> RBC elimination about 4 mo. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Inquire about previous hypersensitivity to sulfonamides prior to therapy.</li>
<li>Withhold drug and notify physician if S&amp;S of local or systemic hypersensitivity occur (see Appendix F).</li>
<li>Withhold the drug and notify the physician if ocular irritation occurs.</li>
<li>Lab tests: Monitor CBC, serum electrolytes, and renal and liver function tests periodically with long-term therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn proper technique for applying eyedrops.</li>
<li>Do not allow tip of drug dipenser to come in contact with the eye.</li>
<li>Discontinue drug and report to physician: ocular irritation, infection, or S&amp;S of systemic hypersensitivity occur (see Appendix
            F).
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>